Sangetsu Corporation (TYO:8130)

Revance Therapeutics Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	30,192	33,727	25,096	24,817	18,347	25,719
Short-Term Investments	300	300	300	300	300	300
Cash & Short-Term Investments	30,492	34,027	25,396	25,117	18,647	26,019
Cash Growth	30.80%	33.99%	1.11%	34.70%	-28.33%	-25.41%
Receivables	55,284	54,596	58,596	55,508	49,411	44,477
Inventory	23,865	22,433	21,787	20,925	17,722	17,109
Other Current Assets	1,733	5,955	1,684	3,293	1,745	1,864
Total Current Assets	111,374	117,011	107,463	104,843	87,525	89,469
Property, Plant & Equipment	42,477	41,665	39,909	36,825	35,285	40,516
Long-Term Investments	18,143	17,696	16,171	14,044	16,648	13,484
Goodwill	2,694	1,836	1,173	1,340	1,474	1,684
Other Intangible Assets	2,408	2,454	2,055	2,172	2,584	8,438
Long-Term Deferred Tax Assets	2,331	3,196	3,978	5,229	4,425	5,233
Other Long-Term Assets	1	1	1	1	2	2
Total Assets	179,428	183,859	170,750	164,454	147,943	158,826
Accounts Payable	31,026	32,097	31,554	29,830	26,551	26,626
Accrued Expenses	1,665	4,067	3,736	3,442	1,983	1,823
Short-Term Debt	2,061	9,098	5,711	801	862	1,169
Current Portion of Long-Term Debt	-	-	-	7,801	1,101	6,092
Current Portion of Leases	495	509	522	439	114	140
Current Income Taxes Payable	764	3,045	2,681	5,734	2,777	1,439
Other Current Liabilities	9,461	9,460	9,069	8,518	7,370	6,501
Total Current Liabilities	45,472	58,276	53,273	56,565	40,758	43,790
Long-Term Debt	12,000	2,000	-	-	7,734	8,660
Long-Term Leases	1,621	1,177	1,251	1,413	284	82
Long-Term Deferred Tax Liabilities	234	254	256	269	395	1,773
Other Long-Term Liabilities	2,597	2,825	2,768	1,833	1,757	1,645
Total Liabilities	67,507	70,079	64,043	68,631	59,619	65,168
Common Stock	13,616	13,616	13,616	13,616	13,616	13,616
Additional Paid-In Capital	17,218	17,218	17,175	17,150	19,773	19,773
Retained Earnings	72,928	74,555	70,799	64,138	54,537	61,387
Treasury Stock	-698	-698	-791	-849	-907	-1,579
Comprehensive Income & Other	8,166	8,344	5,894	1,755	859	238
Total Common Equity	111,230	113,035	106,693	95,810	87,878	93,435
Minority Interest	691	745	14	13	446	223
Shareholders' Equity	111,921	113,780	106,707	95,823	88,324	93,658
Total Liabilities & Equity	179,428	183,859	170,750	164,454	147,943	158,826
Total Debt	16,177	12,784	7,484	10,454	10,095	16,143
Net Cash (Debt)	14,315	21,243	17,912	14,663	8,552	9,876
Net Cash Growth	26.95%	18.60%	22.16%	71.46%	-13.41%	-29.85%
Net Cash Per Share	243.55	361.50	304.94	249.76	143.88	163.05
Filing Date Shares Outstanding	58.77	58.77	58.72	58.68	58.65	60.2
Total Common Shares Outstanding	58.77	58.77	58.72	58.68	58.65	60.31
Working Capital	65,902	58,735	54,190	48,278	46,767	45,679
Book Value Per Share	1892.63	1923.35	1817.08	1632.74	1498.40	1549.15
Tangible Book Value	106,128	108,745	103,465	92,298	83,820	83,313
Tangible Book Value Per Share	1805.82	1850.35	1762.11	1572.89	1429.21	1381.33

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.